ArticleJournal of immunology (Baltimore, Md. : 1950)2001
Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity.
Article in Journal of immunology (Baltimore, Md. : 1950), 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 101 citations in OpenAlex.
- Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2.Human gene therapy · 2008Trial
- Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.Proceedings of the National Academy of Sciences of the United States of America · 2004Trial
- Tcf-1 protects anti-tumor TCR-engineered CD8Cancer immunology, immunotherapy : CII · 2022Article
- Gene Augmentation and Editing to Improve TCR Engineered T Cell Therapy against Solid Tumors.Vaccines · 2020Review
- Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells.Biomaterials science · 2019Article
- Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines.Frontiers in immunology · 2019Review
- Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.Cancer gene therapy · 2017Review
- Strategies to genetically engineer T cells for cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2016Review
- Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors.Oncoimmunology · 2016Review
- Enhancing adoptive T cell immunotherapy with microRNA therapeutics.Seminars in immunology · 2016Review
- Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination.Frontiers in immunology · 2016Review
- Trial Watch: Adoptive cell transfer for oncological indications.Oncoimmunology · 2015Review
- Classification of current anticancer immunotherapies.Oncotarget · 2014Review
- Adoptive immunotherapy for cancer or viruses.Annual review of immunology · 2014Review
- Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking.Frontiers in chemistry · 2014Review
- A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.Journal of immunology research · 2014Review
- Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Genetically modified T cells for the treatment of malignant disease.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2013Review
- Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Oncoimmunology · 2013Article
- Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.Haematologica · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
IL-2-dependent activated cells undergo apoptotic death when IL-2 is withdrawn either in vitro or after in vivo cell transfer. To attempt to sustain their survival after IL-2 withdrawal, melanoma-reactive human T lymphocytes were retrovirally transduced with an exogenous human IL-2 gene. Transduced PBMC and cloned CD8+ T cells produced IL-2 and maintained viability after IL-2 withdrawal. Upon restimulation, IL-2 transductants proliferated in the absence of exogenous IL-2 and could be actively grown, and their survival could be maintained without added IL-2 for over 8 wk. PBMCs similarly transduced with a control vector did not produce IL-2 and failed to proliferate in the absence of IL-2. A CD8+ T cell clone, when transduced with an IL-2 gene, manifested the same phenotypes as PBMCs in the absence of exogenous IL-2. Furthermore, an Ab reactive with the alpha-chain of IL-2R complex reduced the viability mediated by IL-2 secretion of the IL-2 transductants. Moreover, transduction of an IL-2 gene did not affect the high degree of recognition and specificity of transductants against melanoma targets. These tumor-reactive IL-2 transductants may be valuable for in vitro studies and for improved adoptive transfer therapies for patients with metastatic melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.